Life Sciences Archive » February, 2024

Life Sciences - February, 2024

275 articles

• Medtronic Expands Its Bladder Device Patent Fight
• Judge Wary Of Wading Into AG's 'Abortion Pill Reversal' Probe
• BlossomHill Therapeutics Closes $100M Series B
• Sandoz To Pay $265M To Resolve Claims In Price-Fixing MDL
• Auto Co. Says $50M Policy Endorsement Covers COVID Loss
• McCarter & English Wants Ex-Client To Cough Up Extra $1.8M
• Medtronic Says 3 Years Of Tax Returns Under IRS Audit
• Bankrupt Endo To Pay $465M To Resolve Opioid Claims
• 7 Common Myths About Lateral Partner Moves
• Biotech Co., Ex-Exec And Investor To Pay $5.2M In SEC Suit
• Cravath Steers Viatris' $350M Collab With Swiss Co.
• Fish & Richardson Adds Ex-Jenner & Block Life Sciences Duo
• Scrubs Co. Must Arbitrate With Its Ex-Atty Over False Ad Loss
• Judge Says Ermi Counterclaims In Qui Tam Case Can Stand
• Cheering In The NFL Makes Me A Better Lawyer
• WilmerHale Adds Ex-Medtronic Legal Leader To Its DC Office
• 3rd Circ. Won't Rehear Pfizer Shareholder Suit Coverage Row
• Dexcom Rival Fights Its Bid To Tweak Glucose Monitor Patent
• NuVasive Can Pierce Co. To Collect From Ex-Rep, Judge Says
• J&J's CMO Says He Would've Pulled Talc If It Caused Cancer
• Last-Minute Settlement Stops 2nd Catheter Trial In Del.
• Judge Trims Medical Device Royalty Fight
• Hospital Groups Allege Opioid Crisis Damaged Their Finances
• Veradigm To Acquire ScienceIO, Face Potential Nasdaq Delisting
• Monsanto Wants Further 11th Circ. Roundup Suit Review
• 10th Circ. Backs FDA E-Cigarettes Marketing Denial
• Survey Finds Just 4 in 10 Healthcare Orgs. Review AI Guidance
• Args In APA Case Amplify Justices' Focus On Agency Power
• Ga. Judge Pauses $300M Bond Deadline In Monkey Farm Fight
• Arnold & Porter Transactions Vet Joins Foley & Lardner
• Fox Rothschild Taps Sarasota-Area Firm Attys For New Office
• Latham, Jackson Walker Avoid Sanctions Over Sorrento Venue
• Altria Unit Drops Suit Against Dozens Of Vape Makers
• Sales Reps Score $1.6M In Fees After Beating RICO Case
• Bayer Beats Flintstone Vitamin Buyers' Cert. Bid, For Now
• Medical Device Companies Settle Ga. Wrongful Death Suit
• 'Rebel Alliance' Seeks Court Rescue In Opioid Discovery Clash
• Teva Tells 1st Circ. Feds Must Clear High Bar In FCA Case
• Stimwave Prosecutors Accused Of Brady Violation Mid-Trial
• ESG Around The World: Gulf Cooperation Council
• J&J Bankruptcy Could Thwart Accountability For Victims
• Ropes & Gray-Led THL Taking Agiliti Private In $2.5B Deal
• Catching Up With Delaware's Chancery Court
• 1 Pilot For Billionaire Cops Plea, But 2nd Says He's Innocent
• Paul Hastings Adds FDA Practice Chair From King & Spalding
• Cannabis Workers Say Co. Imposed Quotas, Didn't Pay Up
• Chamber's Report Bemoans Biden's March-In Idea For Drug IP
• Healthcare AI Startup Abridge Raises $150M
• 8th Circ. Says Nursing Home Fraudster Owes Supplier $7.6M
• J&J Unit Assails Knee Replacement IP Verdict At Fed. Circ.
• Inside The PTAB's Seagen Cancer Drug Patent Decision
• Walgreens Investors Near Deal In Suit Over Opioid Epidemic
• Judge Nixes McCarter & English Client's Relief Bid In Fee Row
• 6 Pointers For Attys To Build Trust, Credibility On Social Media
• Eye Care Tech Co. Gets Go-Ahead For April Sale In Ch. 11
• Holland & Knight Product Liability Ace Rejoins Reed Smith
• Family Dollar Accused Of Knowingly Selling Unsafe Drugs
• SEC Won't Force BofA To Act On ESG Critic's Proxy Proposal
• Justices Urged To Affirm Limits On Mifepristone Access
• IP Forecast: Samsung Eyes Ex-Attys' Litigation Funder Chats
• NYC Doc Charged Over $20M Lab-Fraud Kickback Scheme
• First-Ever Anti-Doping Act Defendant Sentenced To 3 Months
• Gilead Reaches Deal In Suit Over Counterfeit HIV Drug
• Invisalign Maker Beats Refusal-To-Deal Claims In 3Shape Row
• 3rd Circ. Won't Protect AbbVie's Atty-Client Communications
• Opioid Drug Co. Sued In Del. For Promotion-Tied Stock Drop
• Apple Gets PTAB Wins On 2 Masimo Blood Oxygen Patents
• Sorrento Says US Trustee's Protest Of Texas Venue Off Base
• Biotech VC Firm ORI Capital Closes $260M Fund
• Mich. Judge OKs $52M Deal For Mayo Foundation Subscribers
• Biden Admin's March-In Plan Would Hurt Medical Innovation
• Deals Rumor Mill: Occidental, Kroger-Albertsons, BuzzFeed
• 39 AGs Call For Federal Pharmacy Benefit Manager Reform
• Former Exec Convicted Of Medtronic Insider Trading Scheme
• FDA Let Pharma Co. 'Sidestep' Application Rules, Court Told
• Actelion Cites FDA Safety Rules Against Tracleer Antitrust Suit
• A Post-Mortem Analysis Of Stroock's Demise
• Kratom Buyers Say Sellers Hid Opioid-Like Addiction Risks
• Liberal Justices Hint Chevron Deference Hanging By A Thread
• 2nd Circ. Won't Restore Allergan Investors' Breast Implant Suit
• High Court Blocks Bid By 3 States To Join Abortion Drug Case
• Fluoride Trial Judge Mulls 'Mixed' IQ Evidence In Closings
• US Trustee Wants Sorrento Ch. 11 Tossed Or Relocated
• Ala. Justices Deem Frozen Embryos Children Under State Law
• Patent Atty Group Supports Vanda In High Court Patent Case
• FDA Flags 'Alarming Trend' Of Bad Data In Med Device Testing
• Biotech Co. SomaLogic, Former Exec Settle Fight Over Stock
• Biology AI Startup Bioptimus Raises $35M Seed Round
• Ga. Justices Clarify Official's Role In Hospital Expansion Law
• Pharma Co. Can Get D&O Coverage For Securities Suit
• Fed. Circ. Backs Microsoft's PTAB Win Over 3D Patents
• What's On The Horizon In Attorney General Enforcement
• Latham Adds Cooley Company Growth Pros In San Francisco
• Justices Shoot Down Drugmaker's PTAB Preclusion Challenge
• Preparing For DOJ's Data Analytics Push In FCPA Cases
• High Court Won't Review PTAB's Ax Of Prof's Ventilator Patent
• Judge Seeks Briefing On New Expert Proposed In Tylenol MDL
• Athira Pharma Investors Win OK Of $10M Deal On Second Try
• NC's Stein Supports Abortion Drug Manufacturer In W.Va. Case
• The Congressman Who Reps Cannabis Reform On Capitol Hill
• Va. Couple Sues CooperSurgical Over Destroyed Embryos
• Catching Up With Delaware's Chancery Court
• Reducing The Risk Of PFAS False Advertising Class Actions
• Ape Farm Says Ga. Officials Monkeying With $300M Bond Deal
• Chromocell Hits Stock Markets Following $6.6M IPO
• Medtronic Urges 8th Circ. To Undo Transfer Pricing Ruling
• Taxation With Representation: Paul Weiss, Kirkland
• UK Litigation Roundup: Here's What You Missed In London
• 'Body Sculpting' Device Co. Faces Investor Suit Over Pricing
• IP Forecast: 'No Labels' Party Feuds With Website Over Name
• House Committee Blasts VA, Oracle For E-Record Failures
• DOJ Fights 'Outdated' Tenn. Law On HIV-Positive Sex Workers
• Citadel Securities, Others Beat Biotech Spoofing Suit, For Now
• HHS Targets Biz Group's Standing In Bid To End Medicare Suit
• Profs Say W.Va. Mifepristone Ban 'Out Of Step' With Regs
• Invitae Can Use Cash Collateral For Speedy Ch. 11
• Court Mulls If Claims Buyer Qualifies For Special Ch. 11 Trust
• Freenome Raises $254M For Early Cancer Detection Tests
• Lincare To Pay $25.5M To Settle FCA, Anti-Kickback Litigation
• Aurinia Refocusing After Failed Effort To Find A Buyer
• Med Monitoring Claims In Philips MDL Sent Back For Review
• FTC's Khan Calls Healthcare 'Key' To Fight For Competition
• Pfizer Reaches $93M Deal With Lipitor Buyers In Antitrust MDL
• Alcon Can't Dodge Suit Over Eye Drops' '30 Day Supply' Claim
• Karuna Faces Investor Suit Over $14B Bristol Myers Buyout
• FTC Seeks Info On 'Powerful Middlemen' Amid Drug Shortages
• Adagio Medical Goes Public In $128M SPAC Merger
• Software Co. Inks $4M Deal In Privacy Suit Over Breached Info
• Pharma Co. Humanigen Gets OK For Ch. 11 Sale
• Breast Implant Co. Wants Ch. 11 Sale Closed In 60 Days
• Drug Co. Paratek's Officers Sued In Del. Over $462M Sale
• Biotech Nabs $200M Via Private Placement, Starts CEO Search
• Fox News' Sorrento Report Takes Center Stage At 9th Circ.
• SmileDirectClub Trustee Wants To Cut Leases To Stop Losses
• GSK Exec Joins Troutman Pepper's Life Sciences IP Team
• Coaching High School Wrestling Makes Me A Better Lawyer
• Dentists Can't Get Class Certification In SmileDirectClub Suit
• Genetic Testing Co. Invitae Files For Ch. 11 With $1.5B Debt
• 6th Circ. Backs Drugmakers' Early Win In Diabetes Drug MDL
• Indian Pharma Co. Can't Get Fees In $950M COVID Vax Suit
• Expert's 11th-Hour Change Blocked In Pet Device IP Retrial
• Insurers Must Pay Pharma Co. Defense Costs In SEC Probe
• FDA, Creditors Oppose Drugmaker Humanigen's Ch. 11 Sale
• Texas Appeals Court Grants Medical Coding Co.'s Atty Fee Bid
• Biden Administration Beats Big Pharma Texas Medicare Suit
• New Rule 702 Helps Judges Keep Bad Science Out Of Court
• SG's Office Is Case Study To Help Close Legal Gender Gap
• Ky. Alleges Kroger Had 'Outsized' Role In State's Opioid Crisis
• Mallinckrodt Guts IP Suit Amid Oxide Rival's New Drug App
• Fox Rothschild Beefs Up Government Contracts Team In DC
• Breast Implant Maker Sientra Hits Ch. 11 With $82M In Debt
• Investors Win Class Cert. Against Failed COVID Test Maker
• Alys Pharmaceuticals Launches With $100M In Financing
• Patent Waiver For COVID Meds Would Harm US Biopharma
• Ind. Seed Lab Property Exempt From Tax, Board Says
• Fish & Richardson Launches Life Sciences Group
• Gilead Buying Liver Disease Drugmaker CymaBay For $4.3B
• No More Shady Trading For Ex-FBI Trainee After BigLaw Theft
• DEA Wrong To Block Psilocybin Therapy, 9th Circ. Told
• Pharma Co. Beats Investor Suit Over Licensing Agreement
• Fed. Circ. Backs Gov't Win In Fla. University's Patent Dispute
• Former Pharma Exec Faces Criminal Contempt For Fake Name
• AI Drugmaker Wants Investor Suit Over Botched Trial Tossed
• Healthcare-Focused SPAC Hits The Market After $160M IPO
• FTC Clears AbbVie To Proceed With $10.1B ImmunoGen Buy
• Humanigen Creditors Say DIP Loan Ties Up Too Many Assets
• Conn. Justices Asked To Rule On McCarter Damages Dispute
• Goodwin-Led Gene Editing Firm Metagenomi Raises $94M IPO
• What To Know About 'Novel' Johnson & Johnson ERISA Suit
• 23andMe Led To Late Father And $28M Verdict, Woman Says
• UK Litigation Roundup: Here's What You Missed In London
• $490M FCA Verdict Against Medical Distributor Cut In Half
• White House Patent Plan To Curb Drug Prices Draws Outcry
• SEC Fights Hedge Fund Priest's Fee Bid After Mixed Verdict
• BioNTech Puts $200M Into Collab With Cancer Biotech Autolus
• HHS Won't Invoke IP Rights To Lessen Xtandi Prices
• Biotech Co. Neurona Therapeutics Raises $120M
• Judge Drops Claim From Biotech Ex-VP's Incentive Pay Suit
• FDA Settles Allegations Of Uneven Blood Treatment Standards
• Pharma Cos. Back Request For Justices To Eye Drug IP Case
• Mich. Counties Sue Drug Giants Over Insulin Prices
• Drugmaker Challenges W.Va. Abortion Ban In 4th Circ.
• Investors Sue In Del. For Cartesian Therapeutics Vote Hold
• Skirting Anti-Kickback Causation Standard Amid Circuit Split
• These Firms Are Leading In Patent Litigation Work
• These Firms Are Leading In PTAB Work
• Exelixis GC Joins Board Of Biocom California Organization
• Philips Rival Seeks Interest After Treble Damages Award
• Paul Hastings, Covington Guide Kyverna's Upsized $319M IPO
• Morgan Lewis Adds Hawkins Parnell Toxic Tort Litigator In LA
• EDTX Eclipses WDTX As Top Patent Venue
• PTAB Filings Drop Alongside Declining Patent Litigation
• New Patent Suits Fall To Lowest Level In Over A Decade
• 2nd Circ. Skeptical Of Reviving Investors' Breast Implant Suit
• US Tells 9th Circ. Stem Cell Clinic Not Exempt From FDA Rules
• Fluoride Judge To Attys: 'I Don't Need Perry Mason Moments'
• Life Sciences VC Scion Launches With $310M Fund
• Fla. Justices Hesitant To Limit Abortion Ballot Measure
• Wash. High Court Won't Review J&J Patient Privacy Ruling
• Surgical Robot Co. Sued Over Internal Burns, Death Of Patient
• GOP Lawmakers, AG Spar Over NC Abortion Medication Limits
• Pfizer, Moderna Spar Over Trial Date In COVID Vaccine IP Case
• Acella's $46.5M Drug Recall Settlement Gets Initial Signoff
• Worker Says J&J Mismanaged Prescription Benefits
• 10 Lessons From A Deep Dive Into IP Damages
• Pharma Co. Asks D.C. Judge To Ax FDA's Deadline 'Hall Pass'
• Ward & Smith Nabs $170K Fee In NC Trade Secrets Fight
• What Shareholder Approval Rule Changes Mean For Cos.
• Reimagining Law Firm Culture To Break The Cycle Of Burnout
• Apple Defeats Antitrust Suit By AliveCor Over Apple Watch
• Calif. Lawmakers Pitch New Psychedelics Treatment Bill
• 10th Circ. Affirms $4.7M Stryker Loss, But Tosses Fee Award
• Pacira Touts Stability Upgrade In Pain Drug Patent Trial
• Judge Will Screen Ex-CEO's Filings In Stimwave Ch. 11
• JPML Consolidates Suboxone Dental Decay Suits In Ohio
• 6th Circ. Backs Becton's Win In Royalties Suit
• Expediting Psychedelics Approvals In The EU, UK, Australia
• ESG Around The World: Brazil
• Gilead Ruling Signals That Innovating Can Lead To Liability
• Vidal Should Amend USPTO Precedent In Automaker Review
• NanoString Can Tap $142.5M DIP As It Weighs Ch. 11 Sale
• Grant Compliance Takeaways From Ga. Tech's FCA Settlement
• Competing In Dressage Makes Me A Better Lawyer
• Freshfields Helps Novartis Buy German Pharma In €2.7B Deal
• Psychedelics Bill Roundup: Mass. Proposal Enters Legislature
• 7th Circ. Wary Of Bid To Revive Abbott Formula Claims
• Proposed Class Action Settlement May Cost Acella $46.5M
• Biotech Co. Hit With Investor Suit Over Alzheimer's Drug Trial
• Ozempic Injury Suits Consolidated In Eastern Pa. MDL
• Ga. Sues Federal Gov't Over Medicaid Expansion Program
• Biotech Co. Hits Ch. 11, Blames Drug Misfires, Criminal Case
• CPAP Cleaner Co. Says Philips Can't Pin Recall On It
• Zymergen Ch. 11 Plan Confirmed After Investor Objection
• Teva Asks Fed. Circ. To Examine $177M Verdict Reversal
• Gene-Editing Firm Taps IPO Wave With Plans To Raise $100M
• 3 Firms Guide Merck Animal Health's $1.3B Buy Of Fish Biz
• Spinal Implant Maker Previews Ch. 11 Sale And Wind Down
• Biotech Co. NanoString Hits Ch. 11 In Del. With $325M Debt
• Novo Holdings Buying Biopharma Co. Catalent In $16.5B Deal
• Eli Lilly, Sanofi Beat Antitrust Suit Alleging Insulin Conspiracy
• McKinsey's $78M Opioid Deal With Health Plans Hits Snag
• USPTO Slams Lundbeck's PTSD Drug Patent Term Suit
• 4th Circ. Vacates Va. Doctor's Conviction In Pill Mill Scheme
• Harvard Prof. Slams Study Showing IQ Gains From Fluoride
• ABA Chides 5th Circ. At High Court Over Mifepristone Ruling
• Judge Tosses Involuntary Releases In Amyris Ch. 11 Plan
• Drugmaker Endo Wants To Extend Opioid Suit Pause
• ACLU Atty On How To Protect Civil Liberties In The AI Era
• Families New To Tylenol MDL Cite Expert To Avoid Dismissal
• Latham Led Firms In January IPOs As New Listings Pick Up
• Ascension Says Medical Queries Don't Breach Genetic Privacy
• Pennsylvania AG's Clout In Opioid Deal Likely Has Wide Reach
• How Poor Governance, Weak Contracts Harm Cannabis Cos.
• McCarter & English To Face Revised Biotech Malpractice Suit
• DLA Piper Hires McDermott's FDA Practice Leader In DC
• UK Regulator Examining Thermo Fisher's $3.1B Olink Buy
• 2 Biotech Firms Tap Thawing IPO Market To Raise $239M Total
• Del. Ruling Adds Momentum For Caremark Plaintiffs
• Ex-FDA Leaders Urge High Court To Nix Mifepristone Ruling
• Harvard Professor Testifies Fluoride Is 'Definitely' Neurotoxic
• Stimwave Trustee Seeks Stay Of Perryman Actions In Ch. 11
• Pharma Hikma Reaches $150M Opioid Settlement With States
• Assa Abloy Nabs PTAB Win Against Biometric Security Patent
• Denver Man Accused Of Romancing Women Into $121K Scam
• Bankrupt Pharma Co. Impel Gets OK For $17.5M Sale
• Conn. Supreme Court Snapshot: Sleepy Juror, Surprise Billing
• NJ Says Constitution Doesn't Protect Medical Aid In Dying
• Life Sciences VC Firm Seroba Closes $134M Fund
• Mich. High Court To Consider Lilly Insulin Pricing Probe
• State-Led Generic Drug Cases Removed From MDL
• How Biotech Cos. Can Utilize Synthetic Royalty Financing
• Spinal Implant Maker Eyes Ch. 11 Wind-Down In Del.
• Publicis Reaches $350M Opioid Settlement With All 50 States
• Cell Therapy Firm Kyverna Eyes $200M IPO As Pipeline Builds
• The Legal Industry Needs A Cybersecurity Paradigm Shift